RxDoctor Payments Data

Robert Bendorf, DO

Family Medicine · Harlan, IANPI 1770746620

Payments from drug & device makers

$4,665in general payments, 2019–2025

Across 294 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$686
  • Novo Nordisk$629
  • Novartis$429
  • Amgen$320
  • AstraZeneca$292
  • Pfizer$278
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,665 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$7,758
Medicare patients
26
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$91,079
EliquisApixaban139$83,544
Humira PenAdalimumab12$81,738
JardianceEmpagliflozin64$48,910
MounjaroTirzepatide27$33,938
LinzessLinaclotide25$24,963
EntrestoSacubitril/Valsartan62$24,578
Breo ElliptaFluticasone/Vilanterol38$16,003
VraylarCariprazine Hcl22$15,759
JanuviaSitagliptin Phosphate25$13,432
JanumetSitagliptin Phos/Metformin Hcl38$12,892
FarxigaDapagliflozin Propanediol40$11,644
TradjentaLinagliptin14$8,775
Aimovig AutoinjectorErenumab-Aooe11$8,143
Tresiba Flextouch U-200Insulin Degludec11$8,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$629$91,07997 claims
PfizerEliquis$278$83,544139 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$170$62,95789 claims
AbbVieLinzess, Vraylar$22$40,72247 claims
Lilly USA, LLCMounjaro$686$33,93827 claims
MerckJanuvia, Janumet$117$26,32363 claims
NovartisEntresto$429$24,57862 claims
GSKBreo Ellipta$28$16,00338 claims
AstraZenecaFarxiga$292$11,64440 claims
BayerKerendia$268$7,74812 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$158$5,65312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Harlan

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →